
	Chemical structure search How to Search	Import MOLfile format is only available (V3000 format is not available) Exact match Substructure search Superstructure search Substructure or superstructure search Similarity search

Details
Related links
Search

Co-authoring Researcher

Co-inventing Researcher

Researcher similar to the Researcher

Article similar to the Researcher

Patent similar to the Researcher

Research Project similar to the Researcher

Article(J-GLOBAL estimation)

Patent(J-GLOBAL estimation)

Rchr

J-GLOBAL ID：201801021134687768 Update date: Apr. 17, 2025

Aoki Shigeki

アオキシゲキ | Aoki Shigeki

Clips

Affiliation and department：
Job title： Associate Professor
Homepage URL (1)： http://www.p.chiba-u.jp/lab/yakuzai/

Research field (1)： Clinical pharmacy

Research keywords (6)：グルタミン代謝 , 免疫毒性 , ミトコンドリア , HLA , 特異体質薬物毒性 , がん代謝

Research theme for competitive and other funds (27)：

2025 - 2028 重篤副作用発症に与えるHLAの位置づけの刷新
2025 - 2028 重症薬疹の発症を決定づけるT細胞受容体仮説の証明
2023 - 2028 HLAの翻訳後修飾・輸送に着目した自己免疫の理解
2025 - 2027 HLA発現フォームの違いとバランスに基づく自己指向性免疫の理解
2025 - 2025 分子標的薬寛容性がん細胞集団の均衡維持機構とその破綻戦略の立案

2023 - 2025 HLAの翻訳後修飾・輸送の違いを考慮した自己認識免疫バランスの重要性

2022 - 2025 Mechanistic study of sulfa drug-induced severe cutaneous adverse reactions by focusing on HLA-A*11:01

2021 - 2025 Scientific research of the onset mechanism of drug-induced idiosyncratic toxicity to avoid serious side effects

2020 - 2025 Live imaging of in vivo cancer metabolic reprogramming using PET-CT

2023 - 2024 HLAの翻訳後修飾・輸送機構の理解に基づいた薬物副作用の制御

2022 - 2024 Mechanism of constituting a cancer cell population resistant to molecular-targeted drugs

2021 - 2022 分子標的薬への抵抗性を示すがん細胞“集団”を形成する仕組み

2019 - 2022 ケラチノサイトを用いたHLAの関与する薬疹発症機序の解明

2020 - 2021 マイトファジーによるがん代謝リプログラミングの制御

2019 - 2021 Establishment of effective drug therapy for drug-resistant cancers focusing on reprogramming of glucose metabolism

2020 - 2020 難治性癌細胞に対するマイトファジー制御機構の理解に基づいた糖代謝リプログラミングの抑制

2018 - 2019 HLAの関与する薬物副作用の発症を予測可能なin vitro手法の開発

2019 - 2019 糖代謝リプログラミングの理解に基づいた難治性がん治療標的の探索

2018 - 2019 破骨細胞の寿命を制御するオートファジー~骨粗鬆症の予防へ~

2016 - 2019 Construction of in vitro methods to predict the onset of HLA-mediated idiosyncratic drug toxicity

2016 - 2019 特異体質薬物毒性を再現可能なヒト-マウスキメラ型HLA導入マウスから展開される前向き研究と新規毒性予測法

2015 - 2019 Elucidation of the pathogenesis of idiosyncratic drug-induced liver injury using HLA-transfected mice for establishment of preclinical prediction method

2018 - 2018 破骨細胞のライフサイクルを決定するオートファジー

2017 - 2017 免疫反応の恒常性維持にオートファジーは重要か?

2015 - 2017 Elucidation of the onset mechanism of abacavir-induced severe skin reaction using humanized model animal

2015 - 2016 がんエクソソームに着目した慢性骨髄性白血病治療時の薬剤耐性機構に関する研究

2015 - 2015 次世代の癌治療を目指した癌エクソソームの生物学的意義の解析

Show all

Papers (38)：

Natsumi Hama, Shigeki Aoki, Chun-Bing Chen, Akito Hasegawa, Youichi Ogawa, Marc Vocanson, Hideo Asada, Chia-Yu Chu, Cheng-Che E Lan, Roni P Dodiuk-Gad, et al. Recent progress in Stevens-Johnson syndrome/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment. British Journal of Dermatology. 2024. 192. 1. 9-18
Shigeki Aoki. Elucidating the Mechanisms Underlying Interindividual Differences in the Onset of Adverse Drug Reactions. Biological and Pharmaceutical Bulletin. 2024. 47. 6. 1079-1086
Zhiheng Zhang, Haruna Aoki, Keitaro Umezawa, Joshua Kranrod, Natsumi Miyazaki, Taichi Oshima, Takuya Hirao, Yuri Miura, John Seubert, Kousei Ito, et al. Potential role of lipophagy impairment for anticancer effects of glycolysis-suppressed pancreatic ductal adenocarcinoma cells. Cell Death Discovery. 2024. 10. 1
Akira Kazaoka, Sota Fujimori, Yushiro Yamada, Tomohiro Shirayanagi, Yuying Gao, Saki Kuwahara, Naoki Sakamoto, Takeshi Susukida, Shigeki Aoki, Kousei Ito. HLA-B*57:01-dependent intracellular stress in keratinocytes triggers dermal hypersensitivity reactions to abacavir. PNAS Nexus. 2024. 3. 4
Motoyasu Satou, Jason Wang, Tae Nakano-Tateno, Mariko Teramachi, Shigeki Aoki, Hiroyuki Sugimoto, Constance Chik, Toru Tateno. Autophagy inhibition suppresses hormone production and cell growth in pituitary tumor cells: A potential approach to pituitary tumors. Molecular and Cellular Endocrinology. 2024. 112196-112196

ｍore...

MISC (83)：

SHUN Shiyori, SHUN Shiyori, 薄田健史, 白柳智弘, 青木重樹, 伊藤晃成, 早川芳弘. Development of a novel cancer immunotherapy based on tumor immunogenicity improvement by carbamazepine and HLA-B^*15:02 interaction. 日本薬学会年会要旨集(Web). 2024. 144th
薄田健史, SUN Yuchen, 青木重樹, 伊藤晃成, 早川芳弘. An important role of glycolysis in CD8⁺ T cells in the onset of HLA-mediated idiosyncratic drug toxicity. 日本薬学会年会要旨集(Web). 2024. 144th
Takeshi Susukida, So-Ichiro Sasaki, Tomohiro Shirayanagi, Shigeki Aoki, Kousei Ito, Yoshihiro Hayakawa. Development of a novel strategy for cancer immunotherapy based on tumor immunogenicity improvement by HLA-drug interaction. CANCER RESEARCH. 2023. 83. 7
薄田健史, 青木重樹, SUN Yuchen, 早川芳弘. Glycolysis in CD8⁺ T cells plays an important role in the onset of HLA-mediated idiosyncratic drug toxicity. 日本免疫毒性学会学術年会講演要旨集. 2023. 30th
平尾卓也, 根上窓花, 佐々木文音, 宮田七歌, 青木重樹, 手塚千裕, 加藤芳徳, 山田治美. ミトコンドリアを標的としたBcr-Abl陽性白血病に対する効率的な薬物併用療法の立案. 日本薬学会年会要旨集. 2022. 142年会. 27PO10-16

ｍore...

Books (5)：

医学のあゆみ
医歯薬出版 2024
血液内科
科学評論社 2021
BIO Clinica
北隆館 2020
血液内科
科学評論社 2018
academist Journal
academist Journal 2017

Lectures and oral presentations (201)：

Unveiling HLA's diverse roles through drug-induced immunotoxicity
(第53回日本免疫学会学術集会 2024)
Prediction and evaluation of amino acid residues required for binding of HLA and β2m by in silico analysis
(第53回日本免疫学会学術集会 2024)
Glycolysis in CD8+ T cells plays a major role in the onset of immune-mediated HLA-related idiosyncratic drug-induced toxicity
(第53回日本免疫学会学術集会 2024)
HLAクラスI提示ペプチドの簡便な解析系の開発
(第31回日本免疫毒性学会学術年会 2024)
HLAとβ2-microglobulinの結合有無によるHLA発現様式の違いと免疫毒性的意義の考察
(第31回日本免疫毒性学会学術年会 2024)

ｍore...

Education (4)：

2010 - 2013 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
2008 - 2010 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
2006 - 2008 The University of Tokyo Faculty of Pharmaceutical Sciences Department of Pharmacy
2004 - 2006 The University of Tokyo College of Arts and Sciences

Professional career (1)：

博士(薬学) (東京大学)

Work history (6)：

2024/10 - 現在 Chiba University Graduate School of Pharmaceutical Sciences Associate Professor
2019/04 - 2024/09 Chiba University Graduate School of Pharmaceutical Sciences Lecturer
2018/11 - 2019/03 Chiba University Graduate School of Pharmaceutical Sciences
2013/11 - 2018/10 Chiba University Graduate School of Pharmaceutical Sciences
2013/04 - 2013/10 Pharmaceuticals and Medical Devices Agency

Show all

Committee career (5)：

2022/10 - 現在日本免疫毒性学会連携学会委員
2022/10 - 現在日本免疫毒性学会学術編集委員
2022/07 - 現在日本毒性学会評議員
2019/10 - 現在日本免疫毒性学会評議員
2025/02 - 2027/01 日本薬学会代議員

Awards (9)：

2023/04 - 化学情報協会 JAICI賞薬物副作用の個人差の背景に潜むメカニズムの解明
2023/03 - The Pharmaceutical Society of Japan Award for Young Scientists Elucidation of mechanism underlying individual differences in adverse drug reactions
2021/11 - 日本薬物動態学会第36回年会ベストポスター賞 Elimination of Immunosuppressive Factors Clearly Exhibits Idiosyncratic Toxicity by Abacavir in HLA-B*57:01-Transgenic Mice
2021/07 - 日本毒性学会技術賞ヒトHLAトランスジェニックマウスを用いた特異体質薬物毒性理解への取り組み
2020/09 - 日本薬学会関東支部奨励賞薬物による副作用発症の個人差を決定するHLAの重要性

Show all

Association Membership(s) (7)：

THE JAPANESE SOCIETY FOR THE STUDY OF XENOBIOTICS , THE MOLECULAR BIOLOGY SOCIETY OF JAPAN , THE JAPANESE SOCIETY OF TOXICOLOGY , 日本免疫毒性学会 , THE JAPANESE CANCER ASSOCIATION , THE PHARMACEUTICAL SOCIETY OF JAPAN , 日本免疫学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page


	Free word	※Add the following synonyms, you can increase the number of hits.




		～